SARS-CoV-2-reactive IFN-γ-producing CD4 + and CD8 + T cells in blood do not correlate with clinical severity in unvaccinated critically ill COVID-19 patients혈액 내 SARS-CoV-2 반응성 IFN-γ 생성 CD4 + 및 CD8 + T 세포는 백신 접종을 받지 않은 중환자 COVID-19 환자의 임상 중증도와 상관관계가 없습니다Article Published on 2022-08-222022-09-11 Journal: Scientific Reports [Category] SARS, 바이오마커, 진단, 치료기술, 치료법, [키워드] anti-RBD Anti-RBD IgG association Biomarker Biomarkers Blood blood levels C-reactive protein CD4 CD8 Clinical outcome Clinical severity comparable Concentration correlation COVID-19 patient COVID-19 patients Critically ill critically ill COVID-19 patients D-dimer Deceased detectable died different time point different time points ELISA Enumeration enzyme enzyme-linked immunosorbent assay examined ferritin flow cytometry greater magnitude IFN-γ IgG level increased mortality interleukin interleukin-6 investigated Kinetics Lactose Lower respiratory tract male median age membrane protein Mortality no correlation Patient patients Peripheral blood predict respiratory RNA loads SARS-CoV-2 SARS-CoV-2 RNA SARS-CoV-2 S sera Serum level serum levels specimens spike Spike protein survived Survivors T cell T cell subset T cells T-cell T-cell Response T-cell responses tracheal aspirate Viral viral clearance [DOI] 10.1038/s41598-022-18659-x PMC 바로가기 [Article Type] Article
Observations and Perspectives on Adaptive Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 적응 면역에 대한 관찰 및 전망Article Published on 2022-08-152022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 approved coronavirus coronavirus 2 cross-reactive develop Epitopes help humoral immune immune memory immune response memory natural infection observation pandemic Pandemics Pathogenesis Perspective pre-existing cross-reactive promote PROTECT public health recognize respiratory SARS-CoV-2 SARS-CoV-2 epitope SARS-CoV-2 epitopes SARS-CoV-2-specific T cell SARS-CoV-2-specific T cells Scientific community severe acute respiratory syndrome Coronavirus severe disease T cell T cells T-cell Response T-cell responses Transmission vaccination Vaccine variants variants of concern virus [DOI] 10.1093/cid/ciac310 PMC 바로가기 [Article Type] Article
Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workersSARS-CoV-2 S 펩타이드에 대한 T 세포 반응을 평가하기 위한 상용화된 키트. 의료 종사자를 대상으로 한 파일럿 연구Article Published on 2022-08-122022-09-11 Journal: Medicina clínica [Category] SARS, 진단, 치료기술, [키워드] antibody Antibody test antibody tests Automation BNT162b2-mRNA-COVID-19-vaccine Cell mediated immunity CLIA complement Concordance correlation COVID-19 detect dose ELISA English Ensayos de liberación Interferon-gamma feasibility first vaccination group groups HCW Health care worker IFNγ immune response Immunosuppressed individual Infection Inmunidad Mediada por Células interferon Interferon-gamma-release-assays mRNA natural infection number of sample number of samples peptides pilot study positive Quantitative ranged risk S-protein SARS-CoV-2 SARS-CoV-2 N SARS-CoV-2 S SARS-CoV-2 vaccines Sensitivity and specificity Spanish susceptible T-cell Response T-cell responses vaccine dose Vacuna BNT162b2-mRNA-COVID-19. [DOI] 10.1016/j.medcli.2021.09.013 PMC 바로가기 [Article Type] Article
Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapiesB 세포 고갈 요법을받는 다발성 경화증 환자에서 COVID-19 예방 접종에 대한 강력한 T 세포 활성화Article Published on 2022-08-052022-09-11 Journal: Frontiers in Immunology [Category] SARS, 바이오마커, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive Adaptive immune response Adaptive immunity analyzed anti-CD20 anti-CD20 therapy antibodies antibody production B-cell binding blocking activity BNT162b2 Cellular immune response cellular response Cohort competent Complication condition controls coronavirus COVID-19 COVID-19 vaccination depleting disease driven by form forms hACE2 healthy control humoral Humoral and cellular responses IFNγ IgG antibodies IgG antibody IL-2 immunocompromised individuals Immunotherapy implication individual individuals Infection investigation mRNA mRNA-1273 mRNA-based mRNA-based vaccine multiple sclerosis no difference Ocrelizumab Patient patients proliferation RBD receiving Receptor binding domain recognizing reduced regimen relapsing respiratory rituximab SARS-CoV-2 Seroconversion seroconversion rate severe acute respiratory syndrome Coronavirus significantly significantly higher Spike protein Strong strong T-cell susceptible T-cell T-cell activation T-cell Response therapy vaccination Vaccine design virus infection [DOI] 10.3389/fimmu.2022.926318 PMC 바로가기 [Article Type] Article
Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings다양한 임상 환경에서 면역 저하 환자의 오미크론 변이체에 대한 동형 및 이형 면역 반응Article Published on 2022-08-042022-09-11 Journal: Nature Communications [Category] SARS, 변종, 유전자 메커니즘, 진단, 치료기술, 치료법, [키워드] CD4 CD8 Cellular immune response clinical setting comparable controls cross-neutralization D614G Delta Delta variants disease severity dose Host humoral identify immune immune response immune responses Immunocompromised Immunocompromised patient Immunocompromised patients implication Infection magnitude neutralization neutralizing antibody omicron Organ transplant Patient patients peptide peptide pools Pseudovirus neutralization assay Re-infection recipient response responses risk of infection SARS-CoV-2 severe COVID-19 subset T-cell Response T-cell responses uninfected Vaccine variant variants [DOI] 10.1038/s41467-022-32235-x PMC 바로가기 [Article Type] Article
Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatmentArticle Published on 2022-08-012022-10-05 Journal: ESMO open [Category] 진단, 치료법, [키워드] acute respiratory syndrome anti-spike antibody antibodies baseline BNT162b2 booster booster dose booster vaccination breakthrough infections Cancer cancer patient Cancer patients Care cause CD19+ CD4+ cell counts Cellular immune response cellular immunity cellular response Chemotherapy coronavirus COVID-19 COVID-19 infection died disease dose Efficacy Endocrine evaluated excluded exclusion criteria Factor Factors high risk high-risk population hospital humoral Humoral immunity immune response Immunosuppression immunosuppressive Infection Messenger RNA Mild mRNA mRNA vaccine mRNA-1273 mRNA-based neoplasm neutralizing antibody older patients Other outcome overcome Patient positive reduced required Result severe coronavirus disease significant increase significantly increased significantly lower solid malignancy solid tumors T-cell Response treated Treatment vaccination Vaccine vaccine dose Vaccines were assessed [DOI] 10.1016/j.esmoop.2022.100587 [Article Type] Article
Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant동종 골수 이식 후 2년 미만의 환자에서 1차 COVID-19 예방 접종에 대한 체액 및 세포 반응 손상Article Published on 2022-08-012022-09-11 Journal: British Journal of Haematology [Category] MERS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 adverse outcome adverse outcomes Allogeneic allogeneic bone marrow transplant analysed anti-S IgG Anti-spike BNT162b2 Bone marrow booster Cell Cell-mediated immunity cellular response ChAdOx1 Cohort coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) Coronavirus-2 COVID-19 COVID-19 vaccination Critical defined enzyme-linked immunospot Evidence evidence of haematopoietic stem cell transplant (HSCT) HCs healthy control high risk HSCT HSCT recipient HSCT recipients humoral IFNγ IgG Immunoglobulin Immunoglobulin G ImmunoSpot Impaired interferon less majority Patient Prophylactic prophylactic measure prophylactic measures rate of seroconversion recipient respiratory responders Seroconversion Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) significantly higher significantly lower stem cell T-cell T-cell Response T-cell responses These data titre Transplant vaccination schedule Vaccination strategy Vaccine vaccine immunogenicity Vaccines variants [DOI] 10.1111/bjh.18312 PMC 바로가기 [Article Type] Article
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialChAdOx1 nCoV-19 또는 BNT162b2 2회 접종 및 BNT162b2(COV-BOOST) 3차 접종 후 4차 접종으로 제공된 BNT162b2 및 mRNA-1273 COVID-19 백신의 안전성, 면역원성 및 반응성: 다기관, 맹검, 단계 2, 무작위 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 1:1 95% CI adverse event All participants analysed anti-spike protein IgG assigned blinded block size BNT162b2 boost booster Booster vaccine cellular Cellular and humoral immunity Cellular immune response ChAdOx1 nCoV-19 computer-generated Concentration Controlled trial country COV-BOOST COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Effectiveness ELISA ELISPOT Endpoint enrolled fatigue female Fold change Fold changes force geometric geometric mean groups Humoral immunity immunogenicity Intramuscular injection IQR ISRCTN Laboratory Local male median age median interval Moderna modified intention-to-treat mRNA mRNA-1273 mRNA-1273 booster mRNA-1273 COVID-19 vaccine multicentre of BNT162b2 outcome participant peak per-protocol population Pfizer-BioNTech Phase 2 random randomisation list randomised controlled trial Randomised trial Randomly reactogenicity receive Registered reported representing response Safety SARS-CoV-2 screened Serious Adverse Event seronegative participant seronegative participants serostatus Seven significant increase statistician T-cell Response T-cell responses Task Force the vaccine the vaccines titre treatment allocation Trial upper arm Vaccine variant were assessed wild-type [DOI] 10.1016/S1473-3099(22)00271-7 PMC 바로가기 [Article Type] Clinical Trial
Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review/meta-analysis다발성 경화증에서 SARS-CoV-2 백신 접종에 대한 면역 반응: 체계적인 검토/메타 분석Review Published on 2022-08-012022-09-11 Journal: Annals of Clinical and Translational Neurology [Category] COVID19(2023년), SARS, 치료기술, [키워드] Acetate Affect Alemtuzumab anti-CD20 Antibody detection Antibody Response Antibody responses Antibody testing applied CD20 cellular response Cellular responses Cladribine demonstrated dimethyl fumarate Epidemiology fumarate Glatiramer Glatiramer acetate Google Scholar HCs healthy control immune response Immunity inactivated independent interferon Interferon-beta mAb mAbs Meta-analysis meta-analysis and systematic review monoclonal antibody MOOSE mRNA mRNA vaccine mRNA vaccines multivariate logistic regression multivariate logistic regression model Natalizumab not affect observational studies observational study Odds ratio Patient positive predict response SARS-CoV-2 infections SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines searched seroconversion rate seroconversion rates sphingosine-1-phosphate systematic review T cell T cell response T-cell Response T-cell responses Teriflunomide therapy Vaccine vaccine immunity vaccine response Vaccines vector virus [DOI] 10.1002/acn3.51628 PMC 바로가기 [Article Type] Review
Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade인터루킨-6 차단 후 중증 COVID-19에서 회복된 환자에서 SARS-CoV-2에 대한 강력한 장기 면역Article Published on 2022-08-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 바이오마커, 진단, 치료법, [키워드] 1:1 Affect anti-IL-6 anti-IL-6 therapy anti-IL6 antibody Antibody responses blockade conducted COVID-19 Critical deleterious effect deleterious effects domain Effect evaluated Follow-up greater humoral IgG IgG antibody IL-6 IL-6 blockade Immunity incidence increase in Infection interferon interferon-γ interleukin interleukin-6 Interleukin-6 blockade Laboratory longitudinal cohort study magnitude median Neutralizing antibodies neutralizing antibody no increase Patient patients hospitalized patients with COVID-19 positive proportion Prospective protective immunity receiving Reinfection responded to vaccination response responses risk robust SARS-CoV-2 SARS-COV-2 infection Seropositivity severe COVID-19 Spain subject subjects T-cell T-cell immunity T-cell Response T-cell responses therapy Tocilizumab treated [DOI] 10.1016/j.ebiom.2022.104153 PMC 바로가기 [Article Type] Article